Malignant Endocrine Neoplasm — Trials

Malignant Endocrine Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,801 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 576
Recruiting: 291
Ph III recruiting: 33
Growth YoY: +2.2%
Industry share: 34%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (238)

clinicaltrialsPublishedShowing 51–100 of 365 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06646276	A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).	recruiting	Phase 3	530	Bristol-Myers SquibbINDUSTRY	26	Sep 11, 2026	clinicaltrials
NCT06657222	First in Human Study of TUB-030 in Patients With Advanced Solid Tumors	recruiting	Phase 1 / Phase 2	250	Tubulis GmbHINDUSTRY	5